TARA — Protara Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $52.92m
- -$2.31m
- 27
- 35
- 67
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 15.3 | 34.4 | 47.5 | 67.1 | 43.6 |
Operating Profit | -15.3 | -34.4 | -47.5 | -67.1 | -43.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -15 | -34 | -47.3 | -66 | -40.4 |
Net Income After Taxes | -15 | -34 | -47.3 | -66 | -40.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -15 | -34 | -47.3 | -66 | -40.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15 | -34 | -47.3 | -66 | -40.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -30.1 | -4.7 | -4.21 | -3.24 | -3.57 |